NovoSeven RT (Coagulation factor VIIa [recombinant]) for Hemophilia

Overview
NovoSeven RT is approved by the Food and Drug Administration (FDA) to control and prevent bleeding episodes in children and adults with factor VIII deficiency due to hemophilia A or B. Typically, NovoSeven RT is used to treat people who have developed inhibitors and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions. NovoSeven RT can also be used for perioperative (before, during, and after surgery) care. NovoSeven RT may be used to treat people with acquired hemophilia. The technical name of NovoSeven RT is Coagulation factor VIIa (recombinant).

NovoSeven RT is a clotting factor. Clotting factors work by supplying proteins missing in people with hemophilia.

How do I take it?
Prescribing information states that NovoSeven RT is given as an intravenous injection.

NovoSeven RT comes as a powder that must be reconstituted before injection.

Side effects
The FDA-approved label for Novoseven RT lists common side effects including thrombotic events.

For more details about this treatment, visit:

NovoSevenRT.com

Treatment of Hemophilia – Hemophilia Federation of America